The original version of this article incorrectly reported that Kelli Richard was promoted to vice president of finance and chief financial officer at Invitrogen. In fact, she was promoted to vice president of finance and chief accounting officer.
NEW YORK (GenomeWeb News) — Epigenomics has proposed electing former Roche Diagnostics CEO Heino von Prondzynski to its supervisory board.
The vote would take place during Epigenomics’ next annual general meeting of shareholders. The company made the decision during a March 1 meeting of its supervisory board.
If elected, von Prondzynski would replace Zymogenetics CEO Bruce L.A. Carter.
Von Prondzynski, who said he has known Epigenomics since 2002 when the company and Roche became partners, has “been convinced that their DNA methylation approach to molecular diagnostics is unique and bound to become an integral part of early cancer diagnosis and prognosis."
Invitrogen last week said it has promoted Kelli Richard to be vice president of finance and chief accounting officer, and that Per Peterson has joined the company’s board of directors.
Before joining Invitrogen in 2005, Richard spent 14 years in accounting and financial reporting, and was vice president of accounting and reporting and a principal accounting officer at Gateway.
Peterson recently retired from his role as chairman of research and development at Johnson & Johnson. Before that he was the head of the molecular immunogenetics department and chairman of the department of immunology at the Scripps Research Institute.
Orchid Cellmark has named Bruce Basarab vice president of North American sales and marketing, a newly created position at the company.
Orchid said Basarab formerly was executive vice president of commercial operations for STAT Corp., was a senior vice president of sales and marketing for Geneva Pharmaceuticals, and worked as a sales executive at Ciba-Geigy.
CytRx subsidiary RXi Pharmaceuticals has hired Pamela Pavco as vice president of pharmaceutical development, the company said this week.
Pavco spent 14 years at CytRx and RXi rival Sirna Therapeutics, where she worked to develop the company’s RNAi drug program,
Pavco also worked on several disease areas at Allergan, Targeted Genetics, Eli Lilly, Elan Pharmaceuticals, and Chiron.
Oxford Genome Sciences has appointed Mike Gresser to its scientific advisory board, the company said this week. Gresser is currently a visiting scholar at the Molecular Biology Institute at the University of California, Los Angeles.
He served before that as executive director of biochemistry and molecular biology at the Merck Frost Center for Therapeutic Research in Quebec.
Former Illumina chief scientific officer David Barker has joined NextBio’s board of directors, NextBio said this week.
Before working at Illumina, Barker was chief science advisor at Amersham Biosciences, and served as vice president of research and business development at Molecular Dynamics.
Baker also worked in interdisciplinary neurobiological research at Harvard Medical School.
SensiGen this week said it has named Nicholas Kefalides to the company’s scientific advisory board.
Kefalides was a professor at the University of Pennsylvania for 26 years, and retired from the school in 2006 as professor emeritus.
The company said Kefalides has since been involved in teaching, research, and writing about his area of expertise: the role of connective tissues and basement membranes in degenerative and infectious diseases.
ClinXus, a western-Michigan non-profit promoting the region as a locale for pharmaceutical and medical device companies, this week named John Stark its executive director.
Stark formerly was a sales manager at Affymetrix. He is a native of the region and previously worked as a project manager for the Industrial Experimental and Manufacturing Co., and as an engineer for Motorola’s life sciences segment.
Joel Campbell was named vice president and general manager for Definiens’ US operations, the company said this week. The German image-analysis company said the hire is part of its push to strengthen its US business.
Transgenomic said this week Roland Santoni has resigned from his positions on the company’s board of directors, compensation committee, and audit committee. The company has appointed Rodney Markin to fill the vacancy.
Santoni had served on the company’s board since 2000.
Markin currently is a professor of pathology, microbiology and surgery and senior associate dean for clinical affairs at the College of Medicine at the University of Nebraska. He also is chairman, president and CEO of UNMC, the University of Nebraska’s medical practice.
Bio-Rad Laboratories said that the appointment of Louis Drapeau to the board of directors brings the company back in line with American Stock Exchange listing rules governing the number of directors who must sit on the board’s audit committee.
The company was left with an empty seat on that committee when board member Philip Padou died late in 2006.
Drapeau will face official election to the post at a board meeting in late April.
James Jordan is the new vice president and chief investment officer at the Pittsburgh Life Sciences Greenhouse, the center said this week.
The PLSG is a biotech growth and investment group aiming to spur and facilitate investment and growth programs that links research, technology, and commercialization of biotech enterprises.
In the role, Jordan will be responsible for all of the center’s investment programs and for the Executive-in-Residence program.
The Biophysical Society has awarded its annual award for Outstanding Investigator in Single Molecule Biology to Howard Berg for his work on motility and behavior of flagellated bacteria, US Genomics, which sponsored the award, said this week.
In his bacteria research, Berg “demonstrated the importance of working at the level of single molecules to discover the basis of fundamental cellular processes. Berg is the Herchel Smith Professor of Physics and professor of Molecular and Cellular Biology at Harvard University.
The award was presented this week at the Biophysical Society Awards in Baltimore, Md.
this week said Nicholas Kefalides
has joined its scientific advisory board.
Kefalides holds a Bachelor’s degree from Augustana College in Rock Island, Ill., and an MD degree from the University of Illinois College of Medicine.
He said SensiGen’s AttoSense technology is a “major breakthrough” in detecting viruses and gene products that signal early onset of disease, and that he is “particularly interested in the application of this new technology on the early detection of kidney disease."